Endo International plc, a specialty pharmaceutical company, focuses on branded and generic pharmaceuticals worldwide. The company’s major subsidiary in the United States is Endo Health Solutions Inc. The company’s focus is on the U.S. Branded Pharmaceuticals, the U.S. Generic Pharmaceuticals, and International Pharmaceuticals. In January 2015, the company acquired Auxilium Pharmaceuticals, Inc. (Auxilium), an integrated specialty biopharmaceutical company with a focus on developing and commercializing products for specific patients’ needs. Auxilium, with a range of first- and second-line products across multiple indications, operates in the men’s healthcare sector and focuses its product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. In September 2015, the company acquired Par Pharmaceutical Companies, Inc. (Par), which develops, licenses, manufactures, markets, and distributes pharmaceuticals that help improve patient quality of life. Par focuses on high-barrier-to-entry products that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. Par has operated in two business segments, Par Pharmaceutical, which includes generic products marketed under Par Pharmaceutical and sterile products marketed under Par Sterile Products, LLC; and Par Specialty Pharmaceuticals, which markets three branded products, Nascobal Nasal Spray, Megace ES and Cortisporin-TC Otic Suspension. The company has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX, among others. The company’s non-branded U.S. Generic Pharmaceuticals portfolio consists of a differentiated product portfolio, including tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American, South African and world markets, which the company acquired in the Paladin (Paladin Labs Inc.) acquisition and in the Grupo Farmacéutico Somar, Sociedad Anónima Promotora de Inversión de Capital Variable (Somar) acquisition in 2014. Products U.S. Branded Pharmaceuticals Pain Management Lidoderm: A topical patch product containing lidocaine, Lidoderm was the first U.S. Food & Drug Administration (FDA) approved product for the relief of the pain associated with post-herpetic neuralgia, a condition thought to result after nerve fibers are damaged during a case of Herpes Zoster (commonly known as shingles). The company has a settlement and license agreement with Allergan, plc (Allergan) and Actavis plc, which allowed Allergan to launch its lidocaine patch 5%, a generic version of Lidoderm in 2013. In 2014, the company's U.S. Generic Pharmaceuticals segment launched its authorized generic of Lidoderm. In August 2015, Mylan, Inc. launched a generic version of Lidoderm. OPANA ER: OPANA ER is an opioid agonist indicated for the management of pain severe enough to require daily and long-term opioid treatment and for which alternative treatment options are inadequate. OPANA ER represents the first drug in which oxymorphone is available in an oral, extended-release formulation and is available in 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 30 mg and 40 mg tablets. The FDA approved a new formulation of OPANA ER with INTAC technology. This formulation of OPANA ER with INTAC technology has the same dosage strengths, color and packaging and similar tablet size as original OPANA ER. Percocet: Percocet is approved for the treatment of moderate-to-moderately severe pain. Voltaren Gel: In 2008, the company entered into the 2008 Voltaren Gel Agreement, which was a license and supply agreement with and among Novartis AG and Novartis Consumer Health, Inc. to obtain the exclusive U.S. marketing rights for the prescription medicine Voltaren Gel. In December 2015, the company, Novartis AG and Sandoz, Inc. entered into the 2015 Voltaren Gel Agreement renewing the company’s exclusive U.S. market
endo international plc (ENDP:NASDAQ GS)
Phone: 353 1 268 2000
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for ENDP.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ENDO INTERNATIONAL PLC, please visit www.endo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.